Hanover, Germany

Ivan Ban

This inventor holds 11 USPTO granted patents, plus 1 CIPO patent. Top assignees: Kali-Chemie Pharma Gmbh, Solvay Pharmaceuticals, Gmbh, Abbott Products Gmbh. Active years: 1980-2014.


% Patents Active = 63.6


Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 42(Granted Patents)


Location History:

  • Hanover, DE (1980 - 1998)
  • Hannover, DE (1994 - 2014)

Company Filing History:


Years Active: 1980-2014

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I would generate content for the requested article.

Title: The Inventor Journey of Ivan Ban in Hannover

Introduction:

Ivan Ban, a prolific inventor located in Hannover, DE, has made significant contributions to the field of pharmaceuticals through his innovative patents.

Latest Patents:

1. Method for obtaining a natural mixture of conjugated equine estrogens depleted in non-conjugated lipophilic compounds.

2. Method and apparatus for concentrating and stabilizing conjugated estrogens from mare urine.

Career Highlights:

With an impressive portfolio of 11 patents, Ivan Ban has showcased his expertise in developing methods for extracting natural estrogen mixtures and stabilizing pharmaceutical compounds.

Collaborations:

Throughout his career, Ivan Ban has collaborated with esteemed companies such as Kali-Chemie Pharma GmbH and Solvay Pharmaceuticals GmbH. He has worked closely with colleagues like Heinz-Helmer Rasche and Ulf Preuschoff to bring his inventions to life.

Conclusion:

Ivan Ban's dedication to innovation and his impactful patents in the pharmaceutical industry highlight his exceptional contribution to the field. His cutting-edge methods and collaborations continue to shape advancements in pharmaceutical technology, setting a benchmark for future inventors in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…